Helsinn and Immedica enter exclusive partnership for commercialisation of cancer supportive care products in core European markets LUGANO, Switzerland.
Helsinn closes financing agreement with Oberland Capital Funding secured to expand the portfolio of late- and commercial-stage oncology and rare disease.
Helsinn presents novel data on Chlormethine gel at EORTC cutaneous lymphomas tumors group annual meeting Data on chlormethine in both clinical trials and.
Helsinn appoints Dr Melanie Rolli as Group Chief Operating Officer Lugano, Switzerland, May 19, 2022 – Helsinn Group, a fully integrated, global biopharma.